Integra Lifesciences Holdings CorpIART
What Integra Lifesciences Holdings Corp does.
Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.
We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical (“CSS”) and Tissue Technologies (“TT”). The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care, and otolaryngology, commonly referred to as ear, nose, and throat (“ENT”). We are the world leader in neurosurgery and one of the top three providers in the U.S. in instruments used in precision, specialty, and general surgical procedures. Our TT segment generates about 30% of our overall revenue and focuses on wound reconstruction and care and private label.
We were the first company to receive an FDA claim for regeneration of dermal tissue and are a world leader in regenerative technology. We have developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. We have expanded our base regenerative technology business to include neurosurgical products, ENT, surgical instruments and advanced wound care through global acquisitions and product development to meet the evolving needs of our customers and enhance patient care. Each of these categories and the key products sold therein are described in more detail below. We include financial information regarding our reportable business segments and certain geographic information under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 16. Segment and Geographic Information to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K).
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.5B | $1.6B | $1.5B | $1.6B | $1.6B |
| Net income | $133.9M | $169.1M | $180.6M | $67.7M | -$6.9M | -$516.5M |
| Free cash flow | $164.9M | $264.4M | $222.1M | $73.1M | $25.0M | -$31.1M |
More on IART.
- Integra Lifesciences Holdings Corp summary
- Integra Lifesciences Holdings Corp financial statements
- Integra Lifesciences Holdings Corp key metrics
- Integra Lifesciences Holdings Corp health scores and style box
- Integra Lifesciences Holdings Corp earnings
- Integra Lifesciences Holdings Corp dividends
- Integra Lifesciences Holdings Corp valuation
- Integra Lifesciences Holdings Corp ownership and insiders
- Integra Lifesciences Holdings Corp peers
Figures from Integra Lifesciences Holdings Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.